<DOC>
	<DOCNO>NCT00160888</DOCNO>
	<brief_summary>The objective study assess impact genetic variation ( especially polymorphisms gene cod endothelial nitric oxide synthase ( eNOS ) bradykinin B2 receptor gene ) venous arterial responsiveness vasodilator healthy individual without cardiovascular risk factor .</brief_summary>
	<brief_title>Vasoreactivity Carriers Genetic Polymorphisms</brief_title>
	<detailed_description>Study I : Using dorsal hand vein compliance technique dose-response curve bradykinin sodium nitroprusside obtain healthy volunteer preconstriction phenylephrine pretreatment single dose 500 mg i.v . acetylsalicylic acid . Study II : Using venous occlusion plethysmography dose-response curve acetylcholine , sodium nitroprusside L-NG-monomethyl-arginine ( L-NMMA ) obtain healthy volunteer pretreated single dose 500mg i.v . acetylsalicylic acid .</detailed_description>
	<mesh_term>Bradykinin</mesh_term>
	<mesh_term>Nitroprusside</mesh_term>
	<mesh_term>Acetylcholine</mesh_term>
	<criteria>age : 18 â€“ 70 gender : male good state health know condition cause endothelial dysfunction ( e.g . diabetes , hyperlipidaemia , arterial hypertension , smoking , homocysteinemia ) regular medication and/or treatment drug within last 46 week ( exclusion decide case ) acute chronic illness methylxanthines alcohol 12 hour study nicotine 1 year study drug and/or alcohol abuse pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>